Efficacy of VTP-300 in Chronic Hepatitis B Infection
← catalyst calendarSponsored by Barinthus Biotherapeutics (industry) · BRNS — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
121actual
Sites
18
Countries
Hong Kong, Taiwan, Thailand
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-09-21 | actual | When the study began enrolling |
| Primary completion | 2026-01-13 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-13 | actual | The whole study's end, after follow-up |
| First posted | 2022-04-25 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Hepatitis B
Interventions
- Biological: ChAdOx1-HBV
- Biological: MVA-HBV
- Biological: Nivolumab — also filed as Opdivo 10mg/ml concentrate for solution for infusion
Primary outcome
what the primary-completion date above is the date OFThe incidence of participants with a greater than 1 log HBsAg
measured 6 months after the initiation of therapy
Permalink · BRNS's whole pipeline · Catalyst calendar · Every registered study · What changed